<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181762</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457Q12301</org_study_id>
    <secondary_id>2019-003211-57</secondary_id>
    <nct_id>NCT04181762</nct_id>
  </id_info>
  <brief_title>Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis</brief_title>
  <acronym>SELUNE</acronym>
  <official_title>A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab
      300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects
      with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V
      features).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">January 9, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving Complete Renal Response (CRR)</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of subjects achieving protocol-defined CRR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Urine Protein-to Creatinine Ratio (UPCR)</measure>
    <time_frame>Week 52</time_frame>
    <description>Change from Baseline in 24-hour UPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving Partial Renal Response (PRR)</measure>
    <time_frame>Week 52</time_frame>
    <description>Proportion of subjects achieving protocol-defined PRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dose of oral corticosteroids</measure>
    <time_frame>Week 16 to Week 52</time_frame>
    <description>Average daily dose of oral corticosteroids compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving PRR</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of subjects achieving PRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve CRR</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Time to achieve CRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve PRR</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Time to achieve PRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve UPCR ≤ 0.5 mg/mg</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Time to achieve first morning void UPCR ≤ 0.5 mg/mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in FACIT-Fatigue©</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Improvement in FACIT-Fatigue© mean change of score compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in SF-36 PCS mean</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Improvement in SF-36 PCS mean change compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in LupusQoL Physical Health mean</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Improvement in LupusQoL Physical Health mean change of score compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent AEs (TEAEs) / SAEs</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Incidence of Treatment-emergent AEs (TEAEs) / SAEs from Baseline to Week 52; vital signs and body measurements, standard chemistry and hematology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with CRR at Week 104 within subjects who had achieved CRR at Week 52</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Estimate the proportion of subjects with CRR at Week 104 within subjects who had achieved CRR at Week 52 in the secukinumab group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improved or maintained renal response at Week 104</measure>
    <time_frame>Week 52 to Week 104</time_frame>
    <description>Estimate the proportion of subjects with improved or maintained response (PRR or CRR) in subjects who had achieved at least PRR at Week 52 in the secukinumab group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>secukinumab 300 mg s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>secukinumab placebo s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>secukinumab</intervention_name>
    <description>STUDY DRUG</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female subjects aged 18 - 75 years old at the time of Baseline.

          2. Confirmed diagnosis of:

               -  SLE as defined by the American College of Rheumatology (ACR), OR

               -  LN as the sole clinical criterion in the presence of ANA or anti-dsDNA
                  antibodies.

          3. Active lupus nephritis:

               -  International Society of Neurology/Renal Pathology Society (ISN/RPS) Class III or
                  IV LN [excluding III (C), IV-S (C) and IV-G (C)]; subjects are permitted to have
                  co-existing Class V.

               -  UPCR ≥1 at Screening.

               -  Estimated Glomerular Filtration Rate (eGFR) &gt;30 mL/min/1.73 m2.

               -  Active urinary sediment.

        Exclusion Criteria:

          1. Severe renal impairment and subjects requiring dialysis dialysis within the previous
             12 months before Screening.

          2. Significant medical Problems like myocarditis, pericarditis, severe manifestations of
             neuropsychiatric SLE (NPSLE).

          3. Cyclophosphamide (CYC) use (i.v. or oral) or more than 3000 mg i.v. pulse
             methylprednisolone (cumulative dose) within the month prior to Baseline.

          4. Active ongoing inflammatory diseases.

          5. Previous exposure to secukinumab (AIN457) or any other biologic drug targeting IL-17
             or the IL-17 receptor.

          6. Ongoing infections or malignant process.

          7. Pregnant or lactating women.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa-city</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <zip>92101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>LN</keyword>
  <keyword>secukinumab</keyword>
  <keyword>renal biopsy</keyword>
  <keyword>eGFR</keyword>
  <keyword>UPCR</keyword>
  <keyword>SoC background therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

